Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29921574 | 0.86 | CYP11B2 (0.44) | USP2SMN1; SMN2CYP11B2ACACBGPR183 | |
| SCHEMBL10111390 | 0.83 | USP2 (0.41) | USP2SMN1; SMN2CYP11B2ACACBGPR119 | |
| SCHEMBL904136 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2CYP11B2ACACBGPR183 | |
| SCHEMBL24802886 | 0.80 | GRIN2B (0.37) | USP2SMN1; SMN2CYP11B2CYP11B1ACACB | |
| SCHEMBL21285082 | 0.79 | USP2 (0.47) | USP2SMN1; SMN2CYP11B2ACACBGPR183 | |
| SCHEMBL3495197 | 0.79 | USP2 (0.42) | USP2SMN1; SMN2CYP11B2ACACBGPR119 | |
| SCHEMBL17411222 | 0.79 | USP2 (0.51) | USP2SMN1; SMN2CYP11B2ACACBGPR183 | |
| SCHEMBL27256623 | 0.79 | ALDH1A1 (0.46) | USP2CYP11B2CYP11B1TSHR | |
| SCHEMBL599707 | 0.78 | NAMPT (0.39) | USP2SMN1; SMN2CYP11B2ACACBGPR119 | |
| SCHEMBL346995 | 0.78 | USP2 (0.56) | USP2SMN1; SMN2CYP11B2ACACBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | USP2 4593/4885SMN1; SMN2 3132/4885CYP11B2 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.